Artios Pharma expands with key US hire
Cambridge life science business Artios Pharma, which has already raised $120 million from two major funding rounds, has expanded its US operation by recruiting Tania Dimitrova from Pfizer as chief business officer.
Based at Artios’ new offices in New York City, Dimitrova is leading the UK company’s global partnering and business development strategy and execution as it advances its discovery programmes, including its Polymerase theta (Polθ) technology, towards the market.
The DNA Damage Response (DDR) company is developing a broad pipeline of innovative solutions for hard to treat cancers.
CEO Niall Martin said: “We are thrilled to add Tania, with her impressive track record, to our team. Her bio-pharma industry insights, business and strategic leadership and extensive deal-making experience will be of tremendous value to Artios as we progress through the next few exciting years developing clinically meaningful treatments for cancer patients.”
Dimitrova brings 15 years of bio-pharma business and corporate development, capital markets and investing experience to Artios. At Pfizer she was a director in worldwide business development, leading partnership, licensing, M & A and externalisation transactions.
Prior to Pfizer, she was a member of Bristol-Myers Squibb’s Corporate M & A group where she managed all stages of the origination, due diligence, and execution of M & A and divestiture activities, including multiple buy-side commercial assessments.
She began her career with Credit Suisse Investment Banking as an equity research analyst, where she conducted analyses of private life science companies as they pursued the public markets. She then spent eight years on Wall Street researching and investing in healthcare companies.
Dimitrova said: “DDR therapies have the potential to transform the way we treat cancer and to dramatically improve outcomes for patients. I am thrilled to join Artios, a leader in the DDR space, at such a promising stage of the company’s growth.
Artios was founded by SV Health Investors in 2016 and is led by an experienced scientific and leadership team with expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide.
Headquartered at the Babraham Research Campus in Cambridge, Artios is backed by blue chip investors including Arix Bioscience plc (Artios’ largest shareholder), SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners (formerly EdRIP), LSP, Pfizer Ventures and Novartis Venture Fund (NVF). Artios completed a stunning $84 million Series B financing in 2018, adding to its $36m Series A in September 2016.